AbbVie (NYSE:ABBV) received a $84.00 price target from analysts at BMO Capital Markets in a research note issued to investors on Monday. The firm currently has a “hold” rating on the stock. BMO Capital Markets’ target price points to a potential downside of 11.96% from the company’s previous close.

Other analysts have also issued research reports about the company. Evercore ISI began coverage on AbbVie in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $95.00 price target for the company. SunTrust Banks reaffirmed a “buy” rating and issued a $95.00 price target on shares of AbbVie in a research note on Wednesday, September 13th. UBS lowered AbbVie from a “buy” rating to a “neutral” rating and raised their price target for the stock from $79.00 to $92.00 in a research note on Monday, September 25th. Argus raised their price target on AbbVie from $90.00 to $110.00 and gave the stock a “buy” rating in a research note on Friday, September 29th. Finally, Leerink Swann raised AbbVie from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $89.00 to $106.00 in a research note on Monday, October 2nd. Seven research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $96.66.

Shares of AbbVie (NYSE:ABBV) opened at $95.41 on Monday. AbbVie has a 52 week low of $58.80 and a 52 week high of $98.52. The company has a market capitalization of $152,012.06, a price-to-earnings ratio of 17.93, a P/E/G ratio of 1.34 and a beta of 1.52. The company has a quick ratio of 1.32, a current ratio of 1.45 and a debt-to-equity ratio of 5.08.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 27th. The company reported $1.41 EPS for the quarter, topping analysts’ consensus estimates of $1.39 by $0.02. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. The company had revenue of $7 billion during the quarter, compared to analyst estimates of $7 billion. During the same quarter last year, the firm posted $1.21 earnings per share. The firm’s revenue was up 8.8% on a year-over-year basis. analysts expect that AbbVie will post 5.55 EPS for the current fiscal year.

In related news, SVP Azita Saleki-Gerhardt sold 8,300 shares of AbbVie stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $85.02, for a total value of $705,666.00. Following the completion of the sale, the senior vice president now directly owns 93,099 shares in the company, valued at approximately $7,915,276.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Chairman Richard A. Gonzalez sold 218,193 shares of AbbVie stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $94.01, for a total value of $20,512,323.93. Following the completion of the sale, the chairman now owns 492,030 shares of the company’s stock, valued at $46,255,740.30. The disclosure for this sale can be found here. In the last ninety days, insiders sold 277,125 shares of company stock valued at $25,891,756. 0.23% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MCF Advisors LLC grew its stake in shares of AbbVie by 15.3% during the 1st quarter. MCF Advisors LLC now owns 4,556 shares of the company’s stock valued at $297,000 after purchasing an additional 606 shares during the period. Greatmark Investment Partners Inc. grew its stake in shares of AbbVie by 1.7% during the 1st quarter. Greatmark Investment Partners Inc. now owns 33,936 shares of the company’s stock valued at $2,211,000 after purchasing an additional 560 shares during the period. DekaBank Deutsche Girozentrale grew its stake in shares of AbbVie by 33.4% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 461,768 shares of the company’s stock valued at $30,441,000 after purchasing an additional 115,550 shares during the period. Community Bank N.A. grew its stake in shares of AbbVie by 1.6% during the 1st quarter. Community Bank N.A. now owns 66,262 shares of the company’s stock valued at $4,317,000 after purchasing an additional 1,015 shares during the period. Finally, Massmutual Trust Co. FSB ADV grew its stake in shares of AbbVie by 16.8% during the 1st quarter. Massmutual Trust Co. FSB ADV now owns 98,704 shares of the company’s stock valued at $6,432,000 after purchasing an additional 14,194 shares during the period. Institutional investors own 69.32% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “AbbVie (ABBV) PT Set at $84.00 by BMO Capital Markets” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.thecerbatgem.com/2017/12/06/abbvie-abbv-pt-set-at-84-00-by-bmo-capital-markets.html.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Stock Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related stocks with our FREE daily email newsletter.